Commins Deborah L, Atkinson Roscoe D, Burnett Margaret E
Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA.
Neurosurg Focus. 2007;23(4):E3. doi: 10.3171/FOC-07/10/E3.
The histological appearance of a meningioma is an important predictor of tumor behavior and is frequently a factor in decisions concerning therapy. The relationship between histological features and prognosis is formalized in grading schemes such as those published by the World Health Organization (WHO), most recently in 2007. Although the latest edition is an improvement over previous grading schemes, the WHO scheme still fails to fully address a variety of important issues regarding the relationship between meningioma histological characteristics and behavior. In particular, routine histological examination fails to identify the subset of Grade I tumors that behave aggressively. Because of this, many additional prognostic markers that require immunohistochemical, cytogenetic, or molecular techniques to evaluate are under investigation. Only one, immunohistochemistry for the proliferation marker, Ki 67 (MIB-1), is used routinely and it has only limited utility. It is hoped that an understanding of the genetic changes that underlie tumor progression will improve healthcare professionals' ability to predict the behavior of meningiomas.
脑膜瘤的组织学表现是肿瘤行为的重要预测指标,且常常是治疗决策的一个因素。组织学特征与预后之间的关系在分级方案中得到了规范,例如世界卫生组织(WHO)发布的那些方案,最近一次发布是在2007年。尽管最新版本相较于之前的分级方案有所改进,但WHO方案仍未能充分解决关于脑膜瘤组织学特征与行为之间关系的各种重要问题。特别是,常规组织学检查无法识别出具有侵袭性行为的I级肿瘤子集。因此,许多需要免疫组化、细胞遗传学或分子技术来评估的额外预后标志物正在研究中。目前仅常规使用一种,即针对增殖标志物Ki 67(MIB-1)的免疫组化,但其效用有限。人们希望对肿瘤进展背后的基因变化的了解将提高医疗专业人员预测脑膜瘤行为的能力。